Article
[Specific immunotherapy : clinical experience with recombinant molecular major allergens and hypoallergenic variants].
HNO - 1 Oct 2013
Schendzielorz P, Klimek L
Abstract excerpt
Currently, preparations containing native allergens or allergoids are used predominantly in allergen-specific immunotherapy (SIT) of inhaled allergies. The safety and efficacy of these preparations has been demonstrated. However, their reproducible production and standardisation requires substantial effort. Besides this, improved efficacy is often associated with higher doses and an increase in adverse events....
Topics
Join the communities discussing this publication.